- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02065492
Amlodipine for Myocardial Iron in Thalassemia (AMIT)
Effect of L-type Calcium Channel Blocker (Amlodipine) on Myocardial Iron Deposition in Thalassemic Patients With Moderate to Severe Myocardial Iron Deposition: A Randomized Pilot Study
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Null Hypothesis There is no difference between the efficacy of chelation plus amlodipine therapy and chelation therapy alone in retarding the rate of myocardial iron deposition in thalassemia patients with iron overload and a constant transfusion need.
Alternate Hypothesis Chelation plus amlodipine therapy is more efficacious than chelation therapy alone in retarding the rate of myocardial iron deposition in thalassemia patients with iron overload and a constant transfusion need.
The aim of the investigators study is to determine if amlodipine, an L-type specific calcium channel blocker, in addition to the standard aggressive chelation therapy, can retard the deposition of iron in the myocardium of thalassemia patients with significant myocardial iron load with or without cardiomyopathy.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 74800
- Aga Khan University Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Pediatric patients aged ≥ 6 and ≤ 20 years managed at AKUH for at least 1 year
- ≥ 10 blood transfusion in life time
- Transfusion need ≥ 180 ml/kg/year
- Serum ferritin ≥ 1000 ug/dl
- Patient deemed capable of receiving chelation therapy (by treating hematologist) either subcutaneous infusion of Deferoxamine (Desferal) (3-5 days a week) or oral deferasirox (daily) or Defeperione (oral) or a combination of Desferal and Defeperione.
- Patients who have been on a stable chelation regimen ≥ 6 months
- Completed and signed Informed consent/assent.
Exclusion Criteria:
- Patients with known hypersensitivity to amlodipine.
- Patients with known sinoatrial nodal disease or aortic stenosis.
- Patients with known severe myocardial dysfunction, defined as A LV ejection fraction of ≤ 4 SD for age even without symptoms.
- Patients with known signs and symptoms of heart failure.
- Patients with a T2* value of < 4 ms on cardiac MRI.
- Patients with systolic blood pressures ≤ 2 SD for age (systemic hypotension) at the time of enrolment.
- Patients with previously diagnosed significant congenital heart diseases or acquired heart diseases other than thalassemia (as defined earlier).
- Patients with known contraindications to MRI (pacemakers, cerebral aneurysm metal clips, etc.)
- Patient with a known history of developing tetany after use of a calcium channel blocker
- Known pregnancy.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Standard Chelation & Amlodipine
This arm will receive both chelation and amlodipine. Amlodipine will be administered as a single daily dose. It will be administered at a dose of 0.1 mg/kg/day or maximum of 2.5 mg/day. Standard Chelation therapy will be administered either by subcutaneous infusion of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone. The dosage will depend on individual requirement, as determined by the treating hematologist. |
This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
Other Names:
doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
Other Names:
|
Active Comparator: Standard Chelation
Deferasirox or Deferoxamine or Deferiprone. Patients in this arm will be administered only standard chelation therapy,either by subcutaneous infusion of Chelation therapy of Deferoxamine (3-5 days a week) or oral Deferasirox (daily) or combination of Deferoxamine and Deferiprone. The dosage will depend on individual requirement, as determined by the treating hematologist. This will serve as the control arm of the study without any additional intervention. |
This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of amlodipine in retarding rate of myocardial iron deposition (Assessed by change in T2* times)
Time Frame: At baseline, and then at 6 months and 12 months from the start of the study
|
Each patient will be randomized into either of two study arms: amlodipine plus chelation or chelation alone.
All patients will undergo MRI and T2* imaging at baseline and then at 6 and 12 month follow-up visits.
Efficacy of Amlodipine will be assessed using change in T2* times.
|
At baseline, and then at 6 months and 12 months from the start of the study
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effect of amlodipine therapy on left ventricular size, systolic and diastolic function
Time Frame: At baseline and then at 6 months and 12 months from the start of the study
|
Cardiac MRI and echocardiogram will be utilized to assess both systolic and diastolic function. Basic parameters such as left ventricular end diastolic volume, left ventricular systolic volume and the ejection fraction will be measured. Mitral Inflow Doppler as well as Tissue Doppler Imaging will be used to assess diastolic dysfunction. Conventional Pulsed Doppler Echocardiography will be utilized to derive the myocardial performance index (Tei Index) of each patient which will serve as a surrogate for systolic function. Peak global and segmental longitudinal left and right ventricular strain and strain rate will be calculated using speckle tracking by tracing images obtained from the apical 4-chamber view. Peak global and segmental right and left ventricular circumferential strain and strain rate will also be calculated from a parasternal, mid-cavity short axis view using speckle tracking also. |
At baseline and then at 6 months and 12 months from the start of the study
|
Efficacy of amlodipine in retarding liver iron content (mg/g)
Time Frame: At baseline and then at 6 months and 12 months from the start of the study
|
Liver iron content will be measured using T2* imaging of the liver
|
At baseline and then at 6 months and 12 months from the start of the study
|
Adverse effects of amlodipine therapy
Time Frame: At baseline and at 6 months and 12 months from the start of the study; at all visits to the Clinical Trial Unit pharmacy at the Aga Khan Hosptal for dispensing amlodipine and at all routine visits to the outpatient hematology clinic
|
Data on adverse effects will be be collected using the adverse event form.
The adverse effects anticipated include fatigue, nausea, edema, palpitations, flushing, headache, dizziness, blurred vision, somnolence, cough, hypertension and sinus bradycardia.
Any other adverse event will also be reported.
Adverse events that require only symptomatic management will be treated by the participant's primary hematologist.
Adverse events that require hospitalization will also be managed by the participant's primary hematologist and the costs incurred will be covered by the research fund.
Cardiovascular adverse events that require outpatient or inpatient management will be treated by the Principal Investigator and his cardiology team and all costs incurred will be covered by the research fund.
|
At baseline and at 6 months and 12 months from the start of the study; at all visits to the Clinical Trial Unit pharmacy at the Aga Khan Hosptal for dispensing amlodipine and at all routine visits to the outpatient hematology clinic
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Babar Hasan, Aga Khan University
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Hematologic Diseases
- Genetic Diseases, Inborn
- Anemia
- Anemia, Hemolytic, Congenital
- Anemia, Hemolytic
- Hemoglobinopathies
- Thalassemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Vasodilator Agents
- Membrane Transport Modulators
- Calcium-Regulating Hormones and Agents
- Amlodipine
- Calcium Channel Blockers
Other Study ID Numbers
- AMIT
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thalassemia
-
University of California, San FranciscoRecruitingAlpha-Thalassemia | Alpha Thalassemia Major | Alpha Thalassemia MinorUnited States
-
Agios Pharmaceuticals, Inc.Active, not recruitingTransfusion-dependent Alpha-Thalassemia | Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United States, France, Canada, Malaysia, Germany, Netherlands, Bulgaria, United Kingdom, Turkey, Italy, Greece, United Arab Emirates, Brazil, Denmark, Lebanon, Saudi Arabia
-
Agios Pharmaceuticals, Inc.Active, not recruitingNon-Transfusion-dependent Alpha-Thalassemia | Non-Transfusion-dependent Beta-ThalassemiaSpain, Taiwan, Thailand, United Kingdom, Malaysia, United States, Netherlands, Bulgaria, Turkey, Italy, Canada, Brazil, France, United Arab Emirates, Denmark, Greece, Lebanon, Saudi Arabia
-
University of California, San FranciscoCalifornia Institute for Regenerative Medicine (CIRM)Enrolling by invitationHemoglobinopathies | Alpha Thalassemia Major | Thalassemia Major | Fetal Hydrops | Hemoglobinopathy; With Thalassemia | Fetal Anemia | Alpha; Thalassemia | Thalassemia Alpha | A-ThalassemiaUnited States
-
Editas Medicine, Inc.RecruitingHemoglobinopathies | Thalassemia Major | Thalassemia Intermedia | Transfusion Dependent Beta ThalassemiaUnited States, Canada
-
BGI-researchShenzhen Children's HospitalNot yet recruiting
-
Ionis Pharmaceuticals, Inc.TerminatedBeta Thalassemia IntermediaAustralia, Thailand, Greece, Lebanon, Turkey
-
M.D. Anderson Cancer CenterWithdrawnSickle Cell Disease | Sickle Beta Thalassemia | Beta Thalassemia Major | Sickle Cell-SS Disease | Sickle Beta 0 Thalassemia | Sickle Beta Plus ThalassemiaUnited States
-
Shiraz University of Medical SciencesCompletedCombination Therapy of Hydroxyurea With L-Carnitine and Magnesium Chloride in Thalassemia Intermediaβ-Thalassemia IntermediaIran, Islamic Republic of
-
Vifor (International) Inc.Labcorp Corporation of America Holdings, IncCompletedBeta-Thalassemia | Non-transfusion-dependent ThalassemiaGreece, Israel, Italy, Lebanon, Thailand
Clinical Trials on Standard Chelation
-
National Institute of Diabetes and Digestive and...Completed
-
Optimum Health, Natural Healthcare CenterUnknownChronic Lymphocytic Leukemia
-
Novartis PharmaceuticalsTerminatedAplastic AnemiaRussian Federation
-
Chang Gung Memorial HospitalUnknownInflammation | Anemia | Malnutrition | Lead PoisoningTaiwan
-
Columbia UniversityNational Heart, Lung, and Blood Institute (NHLBI)Terminated
-
Novartis PharmaceuticalsCompletedIron Overload | Myelodysplastic SyndromeUnited States, Canada
-
St. Jude Children's Research HospitalNational Heart, Lung, and Blood Institute (NHLBI)TerminatedHematologic Diseases | Anemia, Sickle Cell | Cerebrovascular Accident | HemochromatosisUnited States
-
Elliott VichinskyCompletedIron Overload | ThalassemiaUnited States
-
Mt. Sinai Medical Center, MiamiCompletedPeripheral Arterial Disease | Critical Limb IschemiaUnited States
-
Case Western Reserve UniversityNational Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Iron Overload | Hemoglobinopathies | Thalassemia | Beta-Thalassemia | Anemia (Iron-Loading)